地中海贫血是一组常见的遗传性血液病,其特征是血红蛋白链合成不足。由于有效的输血和螯合疗法的优化,在过去的几十年中,地中海贫血患者的生存率和总体生活质量有了显著改善。因此,预期寿命的延长导致了一些伴随的发病率的表现,包括心脏病,感染,肝硬化,内分泌异常,各种恶性肿瘤,等等。在这种情况下,关于地中海贫血患者中一些恶性肿瘤病例的概率和最新文献为未来几年建立了新的方案.我们描述了地中海贫血患者发展为糖尿病和头颈癌的第一份报告,并试图总结其现象背后可能的诱发因素和机制。
目前的病例报告描述了一名50岁的亚裔男子,他从小就被诊断患有地中海贫血。2017年初,他还被诊断出患有糖尿病,并开始接受胰岛素降血糖治疗。患者于2013年2月下旬被诊断为原发性非角化性鼻咽未分化癌。2019年3月下旬,左舌活检显示鳞状细胞癌(SCC)。
■我们报告了第一例地中海贫血患者发展为糖尿病和头颈部鳞状细胞癌,并讨论了这三种疾病之间联系的可能性。此特定病例应提醒医生注意地中海贫血患者内分泌疾病和恶性肿瘤的可能性。
UNASSIGNED: Thalassemia is a group of common genetic hematologic disorders characterized by deficient synthesis of the hemoglobin chain. Due to effective blood transfusion and optimization of chelate therapy, the survival of thalassemia patients and their overall quality of life have improved noticeably in the past few decades. As a consequence, the longer life expectancy has led to the manifestation of several concomitant morbidities, including heart disease, infections, cirrhosis, endocrine abnormalities, various malignancies, and so on. In this context, the probability and updated literature about some malignancy cases in patients with thalassemia build new scenarios for the next few years. We describe the first report of a thalassemic patient developing diabetes and head and neck cancer and try to summarize the possible predisposing factors and mechanisms behind their phenomenon.
UNASSIGNED: The current
case report describes a 50-year-old Asian man who has been diagnosed with thalassemia since childhood. In early 2017, he was also diagnosed with diabetes and started on insulin-hypoglycemic treatment. The patient was then diagnosed with primary non-keratinizing undifferentiated carcinoma of the nasopharynx in late February 2013. A biopsy of the left tongue revealed squamous cell carcinoma (SCC) in late March 2019.
UNASSIGNED: We report the first
case of a thalassemic patient developing diabetes and squamous cell carcinoma of the head and neck and discuss the possibility of a link between the three diseases. This specific
case should alert physicians to the possibility of endocrinopathy and malignancy in thalassemic patients.